The role of genetic variations in type I Interferons related to respiratory tract infections in Down Syndrome children.

Completed

• Conditions: Down Syndrome; innate immunity; 10083624; 10027665; 10019815

• Registration Number: NL-OMON32178
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1. Written informed consent from both parents or legal guardian (s).
2. Age 2 until and including 17 years
3. Sex: male and female
4. Ethnic background: Caucasaian and Non-Caucasian
5. Down Syndrome: Trisomy 21 due to meiotic non-dysjunction
6. Siblings: healthy, no known diseases

Exclusion Criteria

1. Not meeting inclusion criteria
2. Clinically ill (infection) at time of venapuncture
3. Down Syndrome: Trisomy 21 due to mitotic non-dysjunction or mosaicism.
4. Siblings: with known congenital, syndromal or immunological disorders or other known diseases

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter is to identify a difference in mRNA expression<br /><br>level of IFN and IFN related genes between 1: Down Syndrome children and a<br /><br>control group of healthy children (siblings) and 2:between different DS<br /><br>children. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary study parameter is to identify a relationship between mRNA<br /><br>expression levels and current/past history of respiratory tract infections in<br /><br>1. DS children compared to siblings and 2. between different DS children.</p><br>